Brought to you by 
Adimab's next antibody partner: Gilead
08 Jan 2013
Executive Summary
Monoclonal antibody developer Adimab LLC has found its tenth partner in just three years, this time in Gilead Sciences Inc. Adimab has agreed to discover fully human monoclonal antibodies against two undisclosed targets for the biotech.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Alliance
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Adimab's next antibody partner: Gilead
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice